Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.
balloon pulmonary angioplasty
chronic thromboembolic pulmonary hypertension
soluble ST2
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
16 Jan 2021
16 Jan 2021
Historique:
received:
09
12
2020
revised:
09
01
2021
accepted:
14
01
2021
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
The aim of the study was to assess soluble ST2 (sST2) concentration and its dynamic changes in the periprocedural period in patients with chronic thromboembolic pulmonary hypertension (CTEPH) treated with balloon pulmonary angioplasty (BPA). We prospectively analyzed 57 procedures of BPA performed in 37 patients with CTEPH. Biomarkers, such as N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T (TnT), and sST2 were assessed at four time points: Before the BPA procedure, 24 h and 48 h after the procedure, and at the discharge from hospital. Each postprocedural period was assessed for complications. Before the BPA procedure, median sST2 concentration was 26.56 ng/mL (IQR: 16.66-40.83 ng/mL). sST2 concentration was significantly higher 24 h and 48 h after the BPA compared to the baseline measurements (33.31 ng/mL (IQR: 20.81-62.56), sST2 concentration in patients with CTEPH treated with BPA changes significantly in the postprocedural period and is significantly higher in the group with complications in postprocedural period.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of the study was to assess soluble ST2 (sST2) concentration and its dynamic changes in the periprocedural period in patients with chronic thromboembolic pulmonary hypertension (CTEPH) treated with balloon pulmonary angioplasty (BPA).
METHODS
METHODS
We prospectively analyzed 57 procedures of BPA performed in 37 patients with CTEPH. Biomarkers, such as N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T (TnT), and sST2 were assessed at four time points: Before the BPA procedure, 24 h and 48 h after the procedure, and at the discharge from hospital. Each postprocedural period was assessed for complications.
RESULTS
RESULTS
Before the BPA procedure, median sST2 concentration was 26.56 ng/mL (IQR: 16.66-40.83 ng/mL). sST2 concentration was significantly higher 24 h and 48 h after the BPA compared to the baseline measurements (33.31 ng/mL (IQR: 20.81-62.56),
CONCLUSIONS
CONCLUSIONS
sST2 concentration in patients with CTEPH treated with BPA changes significantly in the postprocedural period and is significantly higher in the group with complications in postprocedural period.
Identifiants
pubmed: 33467121
pii: diagnostics11010133
doi: 10.3390/diagnostics11010133
pmc: PMC7830401
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Center of Postgraduate Medical Education
ID : 501-1-54-25-18
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Circ Cardiovasc Interv. 2018 Dec;11(12):e005884
pubmed: 30545259
Circ J. 2017 Mar 24;81(4):552-557
pubmed: 28154291
Immunology. 2014 Jan;141(1):9-17
pubmed: 24116703
Eur Respir J. 2013 Jan;41(1):224-32
pubmed: 22903956
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Cardiology. 2012;122(3):158-66
pubmed: 22832599
Int J Cardiol. 2013 Sep 30;168(2):1545-7
pubmed: 23290950
Eur Respir Rev. 2017 Mar 29;26(143):
pubmed: 28356405
JACC Cardiovasc Interv. 2013 Jul;6(7):725-36
pubmed: 23769649
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):628-36
pubmed: 22875884
J Clin Med. 2019 Sep 20;8(10):
pubmed: 31547136
Circ Heart Fail. 2018 Dec;11(12):e005582
pubmed: 30562100
Circ Heart Fail. 2011 Mar;4(2):180-7
pubmed: 21178018
Kardiol Pol. 2013;71(12):1331
pubmed: 24399603
Eur J Clin Invest. 2013 Feb;43(2):113-20
pubmed: 23215810
JAMA Cardiol. 2018 Mar 1;3(3):215-224
pubmed: 29322198
Kardiol Pol. 2017;75(7):645-654
pubmed: 28553870
Circ Heart Fail. 2013 Nov;6(6):1206-13
pubmed: 24114865
Am Heart J. 2010 Oct;160(4):721-8
pubmed: 20934567
Biomarkers. 2020 Nov;25(7):578-586
pubmed: 32901511
Int J Cardiol. 2019 Mar 1;278:232-237
pubmed: 30409735
Rev Port Cardiol. 2017 Feb;36(2):111-125
pubmed: 28117181
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619891529
pubmed: 31878837
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545969
Clin Chim Acta. 2015 Mar 30;443:57-70
pubmed: 25269091
Kardiol Pol. 2015;73(1):63-8
pubmed: 25625343
Eur J Heart Fail. 2011 Jul;13(7):718-25
pubmed: 21551163
Circ Heart Fail. 2013 Nov;6(6):1172-9
pubmed: 24103327
Expert Rev Mol Diagn. 2013 Jan;13(1):13-30
pubmed: 23256700
Int J Cardiol. 2013 Oct 3;168(3):2186-94
pubmed: 23538053
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Clin Chim Acta. 2009 Nov;409(1-2):33-40
pubmed: 19699192
Circ Cardiovasc Imaging. 2013 Sep;6(5):711-21
pubmed: 23811750
Clin Chem. 2012 Dec;58(12):1673-81
pubmed: 23065477
Clin Cardiol. 2014 Jun;37(6):365-70
pubmed: 25068163
J Geriatr Cardiol. 2017 Dec;14(12):766-771
pubmed: 29581716
PLoS One. 2018 Sep 25;13(9):e0204683
pubmed: 30252896
Circulation. 2002 Dec 3;106(23):2961-6
pubmed: 12460879
Clin Chim Acta. 2010 Nov 11;411(21-22):1825-6
pubmed: 20654603
Clin Chem. 2012 Jan;58(1):257-66
pubmed: 22096031
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
J Heart Lung Transplant. 2018 May;37(5):639-646
pubmed: 29329761
Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B
pubmed: 25665766